Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01318902 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01318902 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT01318902, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib) administered orally.
Interventions
- DRUG Dexamethasone
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-04-27 |
| Est. Completion | 2018-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01318902
The ClinicalTrials.gov registry entry for NCT01318902 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01318902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01318902 about?
NCT01318902 is a clinical study titled "Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis". This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib) administered orally.
What is the current status of trial NCT01318902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-04-27. Estimated completion is 2018-11-13.
What interventions are being tested in trial NCT01318902?
The interventions under investigation include: Dexamethasone (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT01318902?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.